St. Jude Children’s Research Hospital investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.
A study led by researchers from MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients.
A clinical guideline from the American Society for Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft tissue sarcoma.
A study has demonstrated that patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions.
Oncology leaders published an article in Cancer Discovery, a journal of the American Association for Cancer Research, on positive changes to cancer clinical trials brought about by the COVID-19 pandemic and recommendations for continuing these changes after the pandemic.
Researchers at Fox Chase Cancer Center found that the odds of a patient undergoing prostate cancer surgery were lower among Black patients compared with white patients during the initial wave of the COVID-19 pandemic.
The COVID-19 pandemic contributed to significant disruptions in breast, colorectal and cervical cancer screenings among federally qualified health systems spanning 15 states across the U.S.
Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective.
In a sign that pain management for patients dying of cancer is worsening, a new study by Dana-Farber Cancer Institute investigators has found a sharp decline in opioid access among these patients over a recent 10-year period, even as many more of them turned to hospital emergency rooms for pain treatment.
Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.